| Gene symbol | CD5 | Synonyms | LEU1, T1 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | CD5 molecule | ||||
| GTO ID | GTC2837 |
| Trial ID | NCT05110742 |
| Disease | Hematologic Cancer |
| Altered gene | CD5 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-NK cell |
| Treatment | CD5 CAR-NK cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances |
| Year | 2021 |
| Country | United States |
| Company sponsor | M.D. Anderson Cancer Center |
| Other ID(s) | 2021-0526 |
| Cohort1: Phase 1 | |||||||||
|
|||||||||
| Cohort2: Phase 2 | |||||||||
|
|||||||||